What is your business idea, what problem do you want to solve?
“Sprint Bioscience’s goal is to cure more people who are diagnosed with cancer. The large drug companies are looking for innovations to broaden their portfolios of drug projects. They do this by buying innovation from small, creative companies such as Sprint Bioscience,” says Jessica Martinsson, Sprint Bioscience CEO.
“We identify, start and develop drug projects in the pre-clinical phase. The goal is to manage these projects, together with a licensee, all the way to a finished product. Our business idea is to develop drug candidates that can be new, innovative treatments by tying up as little capital as possible.
Where are you now?
“Following our move to Flemingsberg, we were able to launch our expansion phase. We now have more than 30 employees, most of whom are working on our research projects as drug chemists and cell biologists. We are a public company, listed on the Nasdaq First North Premier Growth Market, and to date we have signed global licensing agreements for three drug projects,” explains Martinsson.
“Our model differs from how other smaller biotech firms manage and finance drug development. We start new, innovative drug projects and license them in the pre-clinical phase. This allows us to review a project’s commercial value at an early stage, and thereby minimize risk in our project portfolio. Today, we’re known in the international drug industry for delivering projects of high quality and high medical relevance.
What are you plans for the future?
“We have adapted our premises to our specific requirements. Our modern offices and new labs that are suited to how we work and support our creativity,” says Martinsson.
“In the long term, we’ll build a profitable Swedish drug company with an international reputation. We’ll continue to recruit drug developers and other functions to the company.
Why are you based in Flemingsberg?
“Flemingsberg offers us the opportunity to grow and provides a good working environment for our employees. Other advantages are the proximity to research at Karolinska Institutet and the clinical research at Karolinska University Hospital. We are also attracted by Flemingsberg as an area that represents new ways of thinking and we’re excited to see the continued development of the area.”